Rapid de-localization of actin leading edge components with BDM treatment
<p>Abstract</p> <p>Background</p> <p>2,3-Butanedione monoxime (BDM) has been widely used as a non-muscle myosin inhibitor to investigate the role of non-muscle myosinII in the process of actin retrograde flow and other actin cytoskeletal processes. Recent reports show t...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2003-06-01
|
| Series: | BMC Cell Biology |
| Online Access: | http://www.biomedcentral.com/1471-2121/4/5 |